OS Therapies (OSTX) Non-Current Assets (2023 - 2026)
OS Therapies' (OSTX) quarterly Non-Current Assets came in at $6.4 million in Q1 2026, up 4028.54% YoY from $154575.0 in Q1 2025, and down 1.92% on a QoQ basis from $6.5 million in Q4 2025.
OS Therapies (OSTX) Non-Current Assets (2023 - 2026) Analysis & Trends
OS Therapies (OSTX) has 4 years of Non-Current Assets data on file, last reported at $6.4 million in Q1 2026.
- Quarterly Non-Current Assets rose 4028.54% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (up 3541.47% YoY) and the FY2025 annual result came in at $6.5 million, up 123365.31% from the prior year.
- Non-Current Assets slipped to $6.4 million in Q1 2026, from $6.5 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $6.8 million in Q2 2025 to a low of $5270.0 in Q4 2024.
- A 4-year average of $2.6 million and a median of $81312.5 in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2024 — Non-Current Assets tumbled 34.53% — and 2025, when it surged 123365.31%.
- Tracing OSTX's Non-Current Assets over 4 years: stood at $8050.0 in 2023, then plunged by 34.53% to $5270.0 in 2024, then surged by 123365.31% to $6.5 million in 2025, then fell by 1.92% to $6.4 million in 2026.
- The last three Non-Current Assets figures came in at $6.4 million (Q1 2026), $6.5 million (Q4 2025), and $6.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | OS Therapies | 19.46 Mn | 19.46 Mn | - | 6.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.38 Mn |
| Dec 31, 2025 | 6.51 Mn |
| Sep 30, 2025 | 6.63 Mn |
| Jun 30, 2025 | 6.76 Mn |
| Mar 31, 2025 | 154,575.00 |
| Dec 31, 2024 | 5,270.00 |
| Sep 30, 2024 | 6,660.00 |
| Jun 30, 2024 | 6,660.00 |
| Mar 31, 2024 | 7,355.00 |
| Dec 31, 2023 | 8,050.00 |